Non-invasive Spinal Cord Stimulation After Spinal Cord Injury
Launched by UNIVERSITY OF MANITOBA · Feb 14, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment for people who have experienced spinal cord injuries (SCI). The researchers want to see if a method called non-invasive spinal cord stimulation can help improve movement in the trunk and legs when combined with special training on a treadmill. This stimulation uses electrical signals to help activate the nerves in the spinal cord that may not be working properly after an injury.
To be part of this study, participants need to be aged between 20 and 65 and have had a spinal cord injury for at least six months, which has made it difficult for them to move their trunk or legs. They should be in stable health and not need any life-supporting medical equipment. Participants will work with a team to undergo training and stimulation sessions, giving them the opportunity to improve their motor functions and overall mobility. If you or someone you know fits this description and is interested in joining, reaching out to the trial team for more information could be a great step forward.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Has spinal cord injury, 6 mo or longer since injury
- • Is between 20 and 65 years of age
- • Has difficulty with trunk and/or lower limb function
- • Stable medical condition
- • Non-progressive etiology of spinal injury
- • No ventilatory support
- Exclusion Criteria:
- • Genetic or degenerative etiology of spinal injury
- • Need for ventilatory or other life-sustaining medical support
- • History of cardiovascular or pulmonary complications (heart failure, severe hypertension etc.)
About University Of Manitoba
The University of Manitoba, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive expertise in medical research, public health, and community engagement to conduct rigorous and ethical clinical studies. The institution aims to translate scientific findings into practical applications that enhance patient care and improve health outcomes. Committed to fostering a culture of excellence and integrity, the University of Manitoba prioritizes participant safety and scientific validity in all its clinical research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winnipeg, Manitoba, Canada
Winnipeg, Manitoba, Canada
Patients applied
Trial Officials
Katinka Stecina
Principal Investigator
University of Manitoba
Kristine Cowley
Principal Investigator
University of Manitoba
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported